Study of SANTYL® vs Hydrogel (SoloSite®) for Pressure Ulcers

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

3 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-08-31

Study Completion Date

2017-03-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to compare SANTYL® versus hydrogel (SoloSite®) in the treatment of pressure ulcers for participants in a long-term care facility. After meeting study criteria, participants will be randomly assigned for application of SANTYL® or SoloSite® to their pressure ulcer for up to 6 weeks. A study previously conducted showed that in the long-term care setting, the removal of dead skin (debridement) with SANTYL® resulted in more participants achieving complete debridement, more rapidly than when SoloSite® is used. The goal of the present study is to confirm the results of the earlier study, demonstrating superior debridement outcomes for pressure ulcers of patients in long-term care as compared to ulcers managed with SoloSite®.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Use of Santyl Within an Accountable Care Organization

NCT02716519

Pressure Ulcer Foot Ulcer, Diabetic

WITHDRAWN PHASE4

Use of Santyl in Diabetic Foot Ulcers

NCT02581488

Diabetic Foot Foot Ulcer, Diabetic

COMPLETED PHASE4

Effectiveness Study of Santyl Ointment to Treat Pressure Ulcers

NCT01208220

Pressure Ulcer Soft Tissue Necrosis Lower Limb

TERMINATED NA

Using Santyl on Diabetic Foot Ulcers

NCT01408277

Diabetic Foot Ulcers Diabetic Foot Wounds

COMPLETED PHASE4

Santyl Applications to Diabetic Foot Ulcers

NCT02111291

Diabetic Foot Ulcers Diabetic Foot Wounds

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pressure Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Santyl

Santyl collagenase ointment applied topically once per day for up to six weeks

Group Type EXPERIMENTAL

Santyl

Intervention Type BIOLOGICAL

Collagenase ointment applied topically

SoloSite®

SOLOSITE is a hydrogel wound dressing with preservatives. It can donate moisture to rehydrate non-viable tissue. It absorbs exudate while retaining its structure in the wound.

Group Type ACTIVE_COMPARATOR

SoloSite®

Intervention Type BIOLOGICAL

SOLOSITE is a hydrogel wound dressing with preservatives. It can donate moisture to rehydrate non-viable tissue. It absorbs exudate while retaining its structure in the wound.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Santyl

Collagenase ointment applied topically

Intervention Type BIOLOGICAL

SoloSite®

SOLOSITE is a hydrogel wound dressing with preservatives. It can donate moisture to rehydrate non-viable tissue. It absorbs exudate while retaining its structure in the wound.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Provide written informed consent, which will consist of reading, signing, and dating the informed consent document after the Investigator, sub-Investigator or other designated study staff member has explained the study procedures, risks, and contact information.
2. Eighteen (18) years of age or older, of either sex, and of any race.
3. Willing to comply with protocol instructions, including allowing all study assessments.
4. Subject is in-patient in a long-term care facility.
5. A pressure ulcer present with a surface area ≥ 1.0 cm2 and ≤ 64.0 cm2 confirmed using the ImageIQ EDCIQ mobile imaging system. Only one qualifying ulcer per subject will be selected for the study (selection based on greatest clinical need, as assessed by the Investigator).
6. The target ulcer must present with ≥85% necrotic, nonviable tissue as assessed by two independent image reviewers.
7. The target ulcer has not been previously treated with hydrogel (SoloSite®) or with SANTYL®. Prior ulcers at or near the same location may have been treated with these products.
8. No current infections requiring treatment with antibiotics (antibiotic use is permitted for the purpose of urinary tract infection prophylaxis, but this must be explicitly stated in the subject's chart).
9. Acceptable state of health and nutrition with pre-albumin levels of ≥ 10 mg/dL (0.10 g/L), per the Screening local lab report. This is not required if a pre-albumin test within range has been conducted within the last 30 days.
10. A hemoglobin A1c \< 7.9% per the Screening local lab report. This is not required if a hemoglobin A1c test within range has been conducted within the last 30 days.
11. Have adequate pressure redistribution to the affected area or off-loading if the ulcer is on a lower extremity.
12. No known allergies or sensitivities to either test article or the dressings.

Women of child-bearing potential (those who are not premenarchal, not surgically sterilized \[hysterectomy or bilateral oophorectomy\], or not post-menopausal), may participate in the study if they meet the following condition:

-A negative urine pregnancy test at screening

Exclusion Criteria

1. Undergoing therapy with another investigational agent within thirty (30) days of Study Visit 1, or planned participation overlapping with this study.
2. Current oral steroid treatment with a daily dose exceeding 5 mg.
3. Inability to comply with off-loading.
4. If the ulcer is on a lower extremity, inadequate arterial blood flow to the affected limb as evidenced by an ankle brachial index (ABI) \<0.85.
5. Presence of callus requiring surgical debridement within 3 days of Study Visit 1.
6. Target ulcer with exposure of tendon, muscle or bone.
7. Medical condition that, in the opinion of the Investigator, would preclude safe subject participation in the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No